BioCentury | Jan 11, 2016
Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....
BioCentury | Apr 6, 2015
Finance

Up, up and acquired

For the first time since 1Q14, none of the biotech market cap segments fell. While the $200-$499 million tier treaded water, all other segments finished in the black, led by the $1-$4.9 billion segment. Large...
BC Week In Review | Mar 30, 2015
Clinical News

Anthrasil anthrax immune globulin IV regulatory update

FDA approved a BLA from Emergent for Anthrasil anthrax immune globulin IV (AIGIV) to treat inhalational anthrax in combination with antibacterial drugs. The approval triggered a $7 million payment to Emergent from HHS’s Biomedical Advanced...
BC Extra | Mar 26, 2015
Company News

Emergent's anthrax treatment gets FDA nod

FDA approved a BLA for Anthrasil anthrax immune globulin IV (AIGIV) from Emergent BioSolutions Inc. (NYSE:EBS) to treat inhaled anthrax. The drug, developed using plasma collected from healthy donors vaccinated with the company's BioThrax , has...
BC Week In Review | Aug 11, 2014
Clinical News

Anthrax immune globulin IV regulatory update

Emergent submitted a BLA to FDA for Anthrax immune globulin IV (AIGIV) to treat inhaled anthrax. Emergent gained rights to the product - a solution of human polyclonal antibodies that target anthrax toxins - through its acquisition...
BioCentury | Aug 11, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Biodefense company Emergent BioSolutions Inc. (NYSE:EBS) was up $0.44 to $22.47 last week after submitting a BLA to FDA for Anthrax immune globulin IV (AIGIV) to treat inhaled anthrax. AIGIV is being developed...
BC Extra | Aug 8, 2014
Company News

Emergent submits BLA for anthrax treatment

Biodefense company Emergent BioSolutions Inc. (NYSE:EBS) submitted a BLA to FDA for Anthrax immune globulin IV (AIGIV) to treat inhaled anthrax. Emergent gained rights to the product -- a solution of human polyclonal antibodies that...
BioCentury | Sep 12, 2011
Politics, Policy & Law

Biodefense report card

Ten years after 9/11 and the subsequent anthrax attacks alerted America to the threat posed by bioterrorism, progress in developing and procuring vaccines and drugs to protect the civilian population has been frustratingly slow. An...
BC Week In Review | Sep 21, 2009
Clinical News

Anthrax Immune Globulin regulatory update

EMEA's Committee for Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation for Emergent BioSolutions' Anthrax Immune Globulin (AIG) to treat inhalation anthrax disease. The anthrax immune globulin, which was developed...
BC Week In Review | Mar 23, 2009
Clinical News

Anthrax Immune Globulin: Phase I/II started

Emergent BioSolutions began a double-blind, dose-escalation, U.S. Phase I/II trial to compare 3 dose levels of a single IV infusion of AIG vs. Gamunex immune globulin from Talecris Biotherapeutics Inc. (Research Triangle Park, N.C.) in...
Items per page:
1 - 10 of 15